DC-PEACETECH-LAB
24.12.2021 11:02:08 CET | Business Wire | Press release
The International Peace Honors (IPH), created by PeaceTech Lab , an award-winning non-profit organization founded by the United States Institute of Peace , will recognize Forest Whitaker, Ajay Banga, Juanes, Tokata Iron Eyes, Brandon Stanton, Dr. Lisa Su and Nicholas Donofrio for being global change-makers who have positively impacted the world through targeted activism. The virtual event airs Sunday, February 27th, 2022, at 8:00 pm EST. To register to watch visit: internationalpeacehonors.org .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211223005439/en/
“This year’s International Peace Honorees inspire us to greater hope and urgency, by showing what can happen when we leverage technology and media in their highest forms. From promoting peace and non-violence through music, to helping people improve their lives through the digital economy, protect the planet, and raise up a generation of new voices, their tireless work for the betterment of humanity is to be lauded. We are thrilled to recognize each of these outstanding social leaders,” said Sheldon Himelfarb , President & CEO, PeaceTech Lab.
Academy Award Winner, Forest Whitaker will receive the recognition for his everlasting commitment to empowering youth and promoting peace globally. Whitaker is the CEO/Founder of the Whitaker Peace & Development Initiative (WPDI), which provides educational tools and economic opportunities to young people in places touched by exclusion, violence and armed conflict.
Mastercard Executive Chairman, Ajay Banga will receive the honor for his outstanding contributions in bringing the digital economy to over 1 billion people, thus creating a sustainable economy through technology.
Renowned Singer-Songwriter and Social Advocate, Juanes will be honored for his dedication to youth empowerment and peace in his native Colombia through his Mi Sangre Foundation , a peace-building non-profit organization he co-founded alongside Catalina Cock Duque.
Youth Activist, Tokata Iron Eyes is set to be honored for her impassioned advocacy for Indigenous rights and the global climate movement. At age 18, she becomes the youngest person to receive the prestigious award.
Brandon Stanton , the creator of “Humans of New York” , will be celebrated for his dedication to fostering empathy and interconnectedness through powerful storytelling.
AMD ’s President and CEO, Dr. Lisa Su , will be recognized for revolutionizing high performance computing, donating supercomputing power for public good efforts focused on infectious disease research, and for inspiring people from all backgrounds to pursue careers in science and technology.
Lastly, former IBM EVP of Innovation and Technology Nicholas Donofrio , will receive the honor for his contributions to the international community of women and underrepresented youth in the fields of education, engineering, business and mathematics.
“The exceptionalism of our honorees reminds us that we’re all capable of rising to the challenges that negatively affect our world. I’m proud to extol their valuable social contributions and celebrate their vast achievements,” added MariaEsmeralda Paguaga , executive producer of the International Peace Honors .
The host, performers, and special guests will be announced in the upcoming weeks.
The International Peace Honors are made possible with the generosity of its sponsors and donors: Mastercard, BNY Mellon, The MITRE Corporation, Microsoft, Pitney Bowes, Liberty Mutual Insurance, Ernst & Young, Mercator XXI, KUDO, Wipro, and Alliance for Peacebuilding.
Follow @internationalpeacehonors for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005439/en/
Link:
Social Media:
https://www.facebook.com/peacetechlab/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom